Our team
Led by our guiding principle to make everything as simple as possible (but not simpler), we support the nonclinical and translational development of various modalities across different indications. Our team is highly connected with other leading experts from various disciplines to ensure optimal support for our customers.
Bio of our Founder / CEO
Dr. Antje Walz
With over 20 years of experience in translational drug development, Antje has advanced more than 20 differentiated drugs from discovery to early clinical development She has a proven track record of successful IND and CTA submissions for protein therapeutics and small molecules. Her expertise includes translational Pharmacokinetic/Pharmacodynamic modeling and simulation, with a particular interest in bridging the gap from bench to bedside.
Antje has held several positions in biotech, mid and large size companies such as Roche, 3T Biosciences, Pieris and Altana Pharma. She served as Vice President Translational Sciences at 3T Biosciences, DPMK/PD project leader and Head of Translational Modeling & Simulation/Quantitative Systems Pharmacology at F. Hoffmann-La Roche, Ltd. Her work has been widely recognized by the scientific community, with over 2,000 citations to her publications.Antje’s research interests include precision dosing and developing dose optimization strategies to enhance the benefit/risk profile for individual patients.
Antje received her Ph.D. in Biology and Microbiology from the University of Konstanz, Germany.